Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company headquartered in London, United Kingdom, focused on the discovery and development of next-generation antibody-drug conjugates (ADCs). The company describes itself as "an innovative targeted oncology company built on next generation antibody-drug conjugates (ADC) and a novel discovery engine." Its scientific differentiation rests on a proprietary payload called PH1, a spliceosome modulator designed to disrupt RNA splicing within cancer cells — a mechanism distinct from the tubulin inhibitors and DNA-damaging agents used as payloads in most currently approved or late-stage ADCs. Akari's lead candidate, AKTX-101, targets the Trop2 receptor, which is overexpressed on many cancer cells. Using a proprietary linker, AKTX-101 is designed to deliver the PH1 payload directly into the tumor with minimal off-target effects. In preclinical animal models, this splicing modulation has been shown to induce cancer cell death while activating both the innate and adaptive immune system, driving robust and durable activity. Preclinical studies reportedly show significant activity and prolonged survival relative to ADCs with traditional payloads, and AKTX-101 has demonstrated potential synergy with checkpoint inhibitors, both as a single agent and in combination. The PH1 payload has also shown activity against cancer cells driven by key oncogenic drivers such as KRAS, BRAF, ARV7, and FGFR3 fusions. The company has initiated IND-enabling studies for AKTX-101 with the stated goal of starting a first-in-human trial by late 2026 or early 2027. A second candidate, AKTX-102, is an ADC targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. Akari's discovery platform is designed to allow the generation and optimization of ADC candidates against essentially any antigen target of interest. Akari Therapeutics is a publicly traded company, listed on the NASDAQ exchange under the ticker symbol AKTX. Its corporate headquarters are in London, United Kingdom, and its operations and development activities span the United Kingdom and the United States. The company operates in the highly competitive and capital-intensive oncology drug development sector, where its value proposition centers on the novelty of its PH1 payload and the versatility of its ADC discovery engine.

Akari Therapeutics is a clinical-stage oncology biotechnology company headquartered in London, United Kingdom. The company is publicly traded on the NASDAQ exchange under the ticker symbol AKTX. Its corporate identity is centered on the development of next-generation antibody-drug conjugates (ADCs) built on a proprietary discovery engine and a novel payload platform. The company's scientific foundation rests on PH1, a spliceosome modulator that targets RNA splicing. Unlike conventional ADC payloads — which typically consist of tubulin inhibitors or DNA-damaging agents — PH1 is designed to disrupt RNA splicing within cancer cells. This mechanism has been shown in preclinical animal models to induce cancer cell death while simultaneously activating both the innate and adaptive immune systems, a dual mechanism intended to drive robust and durable anti-tumor activity. Akari's lead candidate, AKTX-101, targets the Trop2 receptor, a well-characterized tumor-associated antigen. The candidate employs a proprietary linker designed to deliver the PH1 payload directly into tumor cells with minimal off-target effects. In preclinical studies, AKTX-101 has demonstrated significant activity and prolonged survival relative to ADCs using traditional payloads. It has also shown potential synergy with checkpoint inhibitors, with prolonged survival observed both as a single agent and in combination. The PH1 payload has additionally demonstrated activity against cancer cells harboring key oncogenic drivers such as KRAS, BRAF, ARV7, and FGFR3 fusions. The company has initiated IND-enabling studies for AKTX-101, with a stated goal of beginning a first-in-human trial by late 2026 or early 2027. A second program, AKTX-102, is an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. Akari's discovery platform is designed to enable the generation and optimization of ADC candidates against essentially any antigen target of interest, positioning the company to expand its pipeline beyond its initial programs. As a publicly listed biotechnology company, Akari operates in the capital-intensive oncology drug development sector, where its competitive differentiation rests on the novelty of its PH1 payload and the flexibility of its ADC discovery engine. The company maintains operations and development activities spanning the United Kingdom and the United States.

• Akari Therapeutics is headquartered in London, United Kingdom, and is publicly traded on NASDAQ under the ticker AKTX.

• The company initiates IND-enabling studies for AKTX-101, its lead Trop2-targeting ADC candidate.

• Akari states a goal of starting a first-in-human trial for AKTX-101 by late 2026 or early 2027.

A targeted oncology biotechnology company differentiated by a novel spliceosome-modulator payload (PH1) and a versatile ADC discovery engine, developing next-generation ADCs against validated tumor antigens such as Trop2 and CEACAM5.

• AKTX-101

  Lead ADC candidate targeting the Trop2 receptor, using a proprietary linker to deliver the PH1 spliceosome-modulator payload directly into tumor cells with minimal off-target effects. Preclinical studies show significant activity and prolonged survival relative to ADCs with traditional payloads, with potential synergy with checkpoint inhibitors.

• AKTX-102

  ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors.

• PH1 payload

  A novel spliceosome modulator designed to disrupt RNA splicing within cancer cells. Unlike tubulin inhibitors and DNA-damaging agents used in current ADCs, PH1 has been shown in preclinical models to induce cancer cell death while activating both the innate and adaptive immune system. It has also demonstrated activity against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, and FGFR3 fusions.

• ADC discovery platform

  An innovative discovery engine that enables the generation of ADC candidates and their optimization based on the desired application to any antigen target of interest.

1. 1Akari Therapeutics – Official Websiteakaritx.com
2. 2Akari Therapeutics – Company Overviewakaritx.com
3. 3Akari Therapeutics (United Kingdom) – Wikidatawikidata.org